Results 71 to 80 of about 43,902 (289)

Recent Developments in Osteogenesis Imperfecta [PDF]

, 2015
Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne, Fritz, Jessica M., Harris, Gerald F., Shaker, Joseph L.   +3 more
core   +2 more sources

Targeting the Hyperglycemic Pre‐Metastatic Niche to Prevent Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
Abstract The recent pioneering study by Ye et al. (Adv Sci. 2025;12(37):e0504924) provides compelling evidence that systemic hyperglycemia orchestrates a pre‐metastatic niche (PMN) in bone, promoting breast cancer metastasis and identifying Receptor for Advanced Glycation End‐products (RAGE) inhibition as a viable therapeutic strategy.
DuJiang Yang, Jiexiang Yang, GuoYou Wang
wiley   +1 more source

Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta—the First Prospective Comparative Study

Journal of Clinical Endocrinology and Metabolism
Context Denosumab is a potential therapeutic agent for osteogenesis imperfecta (OI), but its efficacy and safety remain unclear in children with OI.
Jia-Yun Liu, Xiaoyun Lin, Lei Sun, Qian Zhang, Yan Jiang, Ou Wang, X. Xing, Weibo Xia, Mei Li   +8 more
semanticscholar   +1 more source

Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study

Osteoporosis International, 2022
This study examined the effects of denosumab compared to bisphosphonates and vitamin D alone on muscle performance in patients with low BMD. While grip force improved in both the denosumab and bisphosphonate group, a superior increase in chair rising ...
T. Rupp, E. von Vopelius, A. Strahl, R. Oheim, F. Barvencik, M. Amling, T. Rolvien   +6 more
semanticscholar   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, EarlyView.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer, 2019
Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF).
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi, Toshimi Takano   +15 more
doaj   +1 more source

Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Long-term care issues, specifically metabolic bone disorders, are a concern for people living with human immunodeficiency virus (PLWH) who undergo life-long antiretroviral therapy (ART).
Yusuke Kunimoto, Ryosuke Matamura, Hiroshi Ikeda, Hiroto Horiguchi, Satoshi Fujii, Masayoshi Kobune, Masahide Fukudo, Takaki Toda   +7 more
doaj   +1 more source

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [PDF]

, 2015
Purpose: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied.
A Lipton, Ada Braun, Alexander Paterson, Alison T. Stopeck, AM Brufsky, AO Hoff, AT Stopeck, CR Dunstan, D Amadori, Denise Yardley, F Saad, F Saad, Frank Kueppers, GA Block, Huei Wang, Ingo Diel, Janet E. Brown, Jean-Jacques Body, JJ Body, Jorge Arellano, K Fizazi, K Fizazi, Karim Fizazi, Katia Tonkin, L Gedmintas, Lawrence Karsh, LS Rosen, MG Kris, Michael Carducci, Miguel Martín, MR Smith, MR Smith, Neal Shore, NS Tchekmedyian, Paul Sieber, R Paparodis, RE Coleman, RG Russell, S Doshi, SL Ruggiero, ST Chang, Tapan Maniar, XGEVA® (denosumab) US Package Insert, Yasuhiro Fujiwara   +43 more
core   +1 more source

Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study

Osteoporosis International, 2022
To determine denosumab’s effectiveness for fracture prevention among postmenopausal women with osteoporosis in East Asia, the risk of fracture was compared between patients continuing denosumab therapy versus patients discontinuing denosumab after one ...
E. Lai, T. Lin, J. Lange, L. Chen, I. Wong, C. Sing, C.-L. Cheung, S. Shao, Y. Yang   +8 more
semanticscholar   +1 more source

New cell lines expanding the diversity of Ewing sarcoma models

International Journal of Cancer, EarlyView.
What's New? A chromosomal translocation between the EWSR1 and ETS genes is the key oncogenic driver in Ewing sarcoma. EWSR1::FLI1, the most frequent fusion, is subdivided into different fusion types with unclear prognostic relevance. Here, the authors describe the establishment and characterization of four new, intrinsically immortal, patient‐derived ...
Maximilian Kerkhoff, Christiane Schaefer, Wilhelm G. Dirks, Dawid Krzeciesa, Maximilian Bretschneider, Pauline R. Plaumann, Wiebke K. Guder, Arne Streitbürger, Sonja Herter, Heike Peterziel, Ina Oehme, Felina Zahnow, Thomas G. P. Grünewald, Uta Dirksen   +13 more
wiley   +1 more source